Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Who Took Part

According to the abstract, 30 subjects were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Participants included 30 subjects with prior acromegaly and current GHD.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The subjects were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

This was a 6-month, randomized, placebo-controlled study.

The study was conducted at a clinical translational science center.

INTERVENTIONs included GH or placebo.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Body Composition, C-Reactive Protein, Hormone Replacement Therapy, Human Growth Hormone and Quality of Life.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 30 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.